| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1570-0232(02)00674-8 |
| P698 | PubMed publication ID | 12450548 |
| P2093 | author name string | Yan Xu | |
| Jean L Grem | |||
| P2860 | cites work | Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 |
| Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine | Q33502454 | ||
| Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer | Q33855276 | ||
| 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development | Q33925505 | ||
| Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | Q34514696 | ||
| Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study | Q34519158 | ||
| Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer | Q43791689 | ||
| Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients | Q74594881 | ||
| P433 | issue | 1 | |
| P921 | main subject | capecitabine | Q420207 |
| P304 | page(s) | 273-285 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences | Q2422407 |
| P1476 | title | Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma | |
| P478 | volume | 783 |
| Q59136745 | A novel approach to the application of hexagonal mesoporous silica in solid-phase extraction of drugs |
| Q34398312 | A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer |
| Q47327071 | Development and optimization of locust bean gum and sodium alginate interpenetrating polymeric network of capecitabine |
| Q36904564 | Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer |
| Q44604561 | Measurement of anti-cancer agent methoxyamine in plasma by tandem mass spectrometry with on-line sample extraction |
| Q37810210 | Quantification of Polar Drugs in Human Plasma with Liquid Chromatography–Tandem Mass Spectrometry |
| Q39568178 | The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, α-fluoro-β-ureidopropionate, α-fluoro-β-alanine using LC-MS. |
| Q35032865 | Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer |
| Q35212953 | Use of capecitabine in management of early colon cancer |
Search more.